Feb. 8 at 4:32 PM
$MNKD APPROVALS {and eventual accretive} ADDS TO
MNKD SHARE PRICE [Before EOY 2028]:
+
$3 -- acquisition of scPharma [
$SCPH ]
+
$2 -- label change - Afrezza
+
$7 -- pediatric Afrezza
+
$5 -- FDA approval of Furoscix auto injector
+
$2 -- gestational Afrezza
+
$6 -- 2nd Unither DPI drug [
$UTHR ]
+
$6 -- Clofazimine DPI [MNKD-102]
+
$9 -- Nintedanib DPI [MNKD-201]
+
$3 -- TYVASO for IPF
+
$6 -- TYVASO for PPF
--------
+
$49/sh. 🐂
